Subscribe to RSS
DOI: 10.1055/s-2003-43098
Citalopram
CitalopramPublication History
eingereicht: 31.7.2003
akzeptiert: 18.8.2003
Publication Date:
23 October 2003 (online)

Citalopram (Cipramil®, Sepram® und zahlreiche Generika) ist ein zur chemischen Klasse der bizyklischen Isobenzofuran-Derivate gehörender selektiver Serotonin-Wiederaufnahme-Hemmer (SSRI, Abb. [1]). Es wurde 1996 in Deutschland zur Behandlung depressiver Erkrankungen und Panikstörungen zugelassen.
Abb.1 Struktur von Citalopram.
Literatur
- 1
Keller M B.
Citalopram therapy for depression: a review of 10 years of European experience and
data from US clinical trials.
J Clin Psychiatry.
2000;
61
896-908
MissingFormLabel
- 2
Richelson E, Nelson A.
Antagonism by antidepressants of neurotransmitter receptors of normal human brain
in vitro.
J Pharmacol Exp Ther.
1984;
230
94-102
MissingFormLabel
- 3
Milne R J, Goa K L.
Citalopram: a review of its pharmacodynamics and pharmacokinetic properties, and
therapeutic potential in depressive illness.
Drugs.
1991;
41
450-477
MissingFormLabel
- 4
Baumann P.
Pharmacology and pharmacokinetics of citalopram and other SSRIs.
Int Clin Psychopharmacol.
1996;
11
5-11
MissingFormLabel
- 5
Melzacka M, Rurak A, Adamus A, Daniel W.
Distribution of citalopram in the blood serum and in the central nervous system of
rats after single and multiple dosage.
Pol J Pharmacol Pharm.
1984;
36
675-682
MissingFormLabel
- 6 Fachinformation: Citalopram (Sepram®); Stand September 2001
MissingFormLabel
- 7
Brosen K, Naranjo C A.
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.
Eur Neuropsychopharmacol.
2001;
11
275-283
MissingFormLabel
- 8
Montgomery S A, Pedersen V, Tanghoj P, Rasmussen C, Rioux P.
The optimal dosing regimen for citalopram - a meta-analysis of nine placebo controlled
studies.
Int Clin Psychopharmacol.
1994;
9
35-40
MissingFormLabel
- 9
Parker N G, Brown C S.
Citalopram in the treatment of depression.
Ann Pharmacother.
2000;
34
761-771
MissingFormLabel
- 10
Feighner J P, Overo K.
Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe
depression.
J Clin Psychiatry.
1999;
60
824-830
MissingFormLabel
- 11
Mendels J, Kiev A, Fabre L F.
Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.
Depress Anxiety.
1999;
9
54-60
MissingFormLabel
- 12
Pollock B G.
Citalopram: a comprehensive review Expert.
Opin Pharmacother.
2001;
2
681-698
MissingFormLabel
- 13
Patris M, Bouchard J M, Bougerol T, Charbonnier J F, Chevalier J F, Clerc G. et al .
Citalopram versus fluoxetine: a double-blind, controlled, multicenter, phase III
trial in patients with unipolar major depression treated in general practice.
Int Clin Psychopharmacol.
1996;
11
129-136
MissingFormLabel
- 14
Haffmans P MJ, Timmerman L, Hooqduin C A.
Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed
outpatients: a double-blind, multicenter study.
Int Clin Psychopharmacol.
1996;
11
157-164
MissingFormLabel
- 15
Ekselius L, von Knorring L, Eberhand G.
A double-blind multicenter trial comparing sertraline and citalopram in patients
with major depression treated in general practice.
Int Clin Psychopharmacol.
1997;
12
323-331
MissingFormLabel
- 16
de Wilde J, Mertens C, Overo K F, Petersen H E.
Citalopram versus mianserin: A controlled, double-blind trial in depressed patients.
Acta Psychiatr Scand.
1985;
72
89-96
MissingFormLabel
- 17
Ahlfors U G, Elovaura S, Harma P. et al .
Clinical multi-centre study of citalopram compared double-blindly with mianserin
in depressed patients in Finland.
Nord Psykiatr Tidsskr.
1988;
42
201
MissingFormLabel
- 18
Bouchard J M, Delaunay J, Delisle J P, Grasset N, Mermberg P F, Molczadzki M, Pagot R, Richou H, Robert G, Ropert R. et al .
Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed
patients.
Acta Psychiatr Scand.
1987;
76
583-592
MissingFormLabel
- 19
Rosenberg C, Damsbo N, Fuglum E, Jacobsen L V, Horsgard S.
Citalopram and imipramine in the treatment of depressive patients in general practice.
A Nordic multicenter study.
Int Clin Psychopharmacol.
1994;
9
41-48
MissingFormLabel
- 20
Shaw D M, Thomas D R, Briscoe M H, Watkins S E, Crimmins R.
A comparison of the antidepressant action of citalopram and amitriptyline.
Br J Psychiatry.
1986;
149
515-517
MissingFormLabel
- 21
Gravem A, Amthor K F, Astrup C, Elgen K, Gjessing L R, Gunby B. et al .
A double-blind comparison of citalopram (Lu 10 - 171) and amitriptyline in depressed
patients.
Acta Psychiatr Scand.
1987;
75
478-486
MissingFormLabel
- 22
Danish University Antidepressant Group .
Citalopram: clinical effect profile in comparison with clomipramine. A controlled
multicenter study.
Psychopharmacology (Berl).
1986;
90
131-138
MissingFormLabel
- 23
Baumann P, Nil R, Bertschy G, Jecker A, Brandli H, Morand J, Kasas A, Vuagniaux O, Ramseier F.
A double-blind double-dummy study of citalopram comparing infusion versus oral administration.
J Affect Disord.
1998;
49
203-210
MissingFormLabel
- 24
Guelfi J D, Strub N, Loft H.
Efficacy of intravenous citalopram compared with oral citalopram for severe depression.
Safety andefficacy data from a double-blind, double-dummy trial.
J Affect Disord.
2000;
58
201-209
MissingFormLabel
- 25
Montgomery S A, Rasmussen J G, Tanghoj P.
A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention
of relapse of major depression.
Int Clin Psychopharmacol.
1993;
8
181-188
MissingFormLabel
- 26
Wade A G, Lepola U, Koponen H J, Pedersen V, Pedersen T.
The effect of citalopram in panic disorder.
Br J Psychiatry.
1997;
170
549-553
MissingFormLabel
- 27
Ostrom M, Eriksson A, Thorson J, Spigset O.
Fatal overdose with citalopram.
Lancet.
1996;
348
339-340
MissingFormLabel
- 28 Arzneimittel-Telegramm 1996 96: 106-107
MissingFormLabel
- 29
Rasmussen S L, Overo K F, Tanghoj P.
Cardiac safety of citalopram: prospective trials and retrospective analyses.
J Clin Psychopharmacol.
1999;
19
407-415
MissingFormLabel
- 30
Meuleman C, Jourdain P, Bellorini M, Sadeg N, Loiret J, Guillard N, Thebault B, Funck F.
Citalopram and Torsades de Pointes: A case report.
Arch Mal Coeur Vaiss.
2001;
94
1021-1024
MissingFormLabel
- 31
Catalano G, Catalano M C, Epstein M A, Tsambiras P E.
QTc interval prolongation associated with citalopram overdose: a case report and
literature review.
Clin Neuropharmacol.
2001;
24
158-156
MissingFormLabel
- 32
Rothenhausler H B, Hoberl C, Ehrentrout S, Kapfhammer H P, Weber M M.
Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia,
hypotension and syncopes: successful therapy with a temporary pacemaker.
Pharmacopsychiatry.
2000;
33
150-152
MissingFormLabel
- 33
Barbey J T, Roose S P.
SSRI safety in overdose.
J Clin Psychiatry.
1998;
59
42-48
MissingFormLabel
- 34
Waugh J, Goa K L.
Escitalopram: a review of its use in the management of major depressive and anxiety
disorders.
CNS Drugs.
2003;
17
343-362
MissingFormLabel
- 35
Lepola U M, Loft H, Reines E H.
Escitalopram (10 - 20 mg/day) is effective and well tolerated in a placebo-controlled
study in depression in primary care.
Int Clin Psychopharmacol.
2003;
18
211-217
MissingFormLabel
- 36 Laux G, Dietmaier O, König W. Pharmakopsychiatrie. Urban und Fischer Verlag 2001
MissingFormLabel
- 37
Greenblatt D J, von Moltke L L, Harmatz J S, Shader R I.
Drug interactions with newer antidepressants: role of human cytochromes P450.
J Clin Psychiatry.
1998;
59
(Suppl 15)
19-27
MissingFormLabel
- 38
Dalton S O, Johansen C, Mellemkjaer L, Norgard B, Sorensen H T, Olsen J H.
Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal
tract bleeding: a population-based cohort study.
Arch Intern Med.
2003;
163
59-64
MissingFormLabel
- 39
de Abajo F J, Rodriguez L A, Montero D S.
Association between selective serotonin reuptake inhibitors and upper gastrointestinal
bleeding: population based case-control study.
BMJ.
1999;
319
1106-9
MissingFormLabel
Prof. Dr. Thomas Eschenhagen
Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg